LOGIN  |  REGISTER
C4 Therapeutics
C4 Therapeutics

Elevance Health to Hold Conference Call and Webcast to Discuss Second Quarter 2025 Results on July 17

July 02, 2025 | Last Trade: US$349.63 2.75 0.79

INDIANAPOLIS / Jul 02, 2025 / Business Wire / Elevance Health (NYSE: ELV) will release second quarter 2025 financial results on July 17, 2025, at 6:00 a.m. Eastern Daylight Time (“EDT”). Management will review these results and its outlook during a conference call at 8:30 a.m. EDT that same morning. The conference call should be accessed at least 15 minutes prior to its start with the following numbers:

  • 888-947-9963 - Access Code - 3972058 (Domestic)
  • 312-470-0178 - Access Code - 3972058 (International)
  • 866-511-1890 - No Access Code (Domestic Replay)
  • 203-369-1945 - No Access Code (International Replay)

The replay will be available from 11:30 a.m. EDT on July 17, 2025, until the end of the day on August 15, 2025. The call will also be available through a live webcast at www.elevancehealth.com under the “Investors” link. You may also access the webcast here. A webcast replay will be available following the call.

About Elevance Health

Elevance Health is a lifetime, trusted health partner whose purpose is to improve the health of humanity. The company supports consumers, families, and communities across the entire healthcare journey – connecting them to the care, support, and resources they need to lead better lives. Elevance Health’s companies serve over 110 million consumers through a diverse portfolio of industry-leading medical, pharmacy, behavioral, clinical, home health, and complex care solutions. For more information, please visit www.elevancehealth.com or follow us @ElevanceHealth on X and Elevance Health on LinkedIn.

Chimerix

Stock Quote

Featured Stock

Amneal Pharmaceuticals

Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...

CLICK TO LEARN MORE

Featured Stock

Chimerix

Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....

CLICK TO LEARN MORE

End of content

No more pages to load

Next page